Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00514605|
Recruitment Status : Completed
First Posted : August 10, 2007
Last Update Posted : December 12, 2007
Each year up to 22 million persons in the US are tested for HIV. Currently available "rapid" tests do not provide test results for at least 30 minutes from the collection of serum and plasma from the subject. Providing accurate test results in less than a minute would make it easier to make timely decisions about treatment and counselling.
This study will compare results of an experimental rapid test to existing standards to determine if the test can reliably and accurately diagnose HIV in less than one minute.
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Other: Behavioral counseling Device: HIV-1 Antibody Test Kit||Phase 2 Phase 3|
The primary objective is to determine if INSTI™ performed with finger-stick whole blood, venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity compared to an FDA-approved HIV testing algorithm.
The study will have two parts. The first part of the study will be conducted in institutions where HIV testing is routinely performed and where HIV counseling is offered [i.e. point of care (POC) centers]. The second part of the study will be conducted in a central laboratory that routinely conducts laboratory-based HIV testing using an FDA-licensed HIV-1 ELISA and Western blot test.
Geographically diverse POCs will be selected in the USA. Approximately 15-20 POCs are planned. Approximately 2,500 subjects will participate in the study including 1,500 subjects with unknown HIV status and 1,000 seropositive subjects. Across these POC sites, voluntary testing of 1500 subjects with unknown HIV status is planned with at least 500 of these subjects being high risk. Samples will be obtained from consenting subjects in the voluntary testing population including high-risk and known HIV 1 seropositive individuals.
Each subject is to receive an INSTI™ on finger-stick blood and parallel HIV testing of EDTA-treated venous whole blood and plasma samples will be conducted at a central laboratory.
The results of INSTI™ will not be given to the subject. The subject will be given the results of the POC HIV test only, per their standard of care procedures. Subsequent subject care decisions will NOT be based on the results of INSTI™.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2500 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Study to Evaluate the Point-of-Care Use and Laboratory Investigational Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection|
|Study Start Date :||July 2007|
- Other: Behavioral counseling
Standard-of-Care counseling at the Point-of-Care.
- Device: HIV-1 Antibody Test Kit
Assay to detect HIV antibodiesOther Name: INSTI™ HIV-1 Antibody Test Kit
- INSTI™ performed with finger-stick whole blood, venous whole blood, and plasma demonstrates at least 98.0% sensitivity and specificity compared to an FDA-approved HIV testing algorithm [ Time Frame: <1 week ]
- The percentage of INSTI™ results that agree between finger-stick whole blood, venous whole blood, and plasma. [ Time Frame: < 1 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00514605
|United States, California|
|LA County STD Program|
|Los Angeles, California, United States, 90007|
|Michael Sumero, MD|
|Palm Springs, California, United States, 92262|
|UCSD Antiviral Research Center|
|San Diego, California, United States, 92103|
|United States, Colorado|
|Denver Public Health|
|Denver, Colorado, United States, 80204|
|United States, Florida|
|Fort Lauderdale, Florida, United States, 33306|
|United States, Maryland|
|University of Maryland, Baltimore School of Medicine|
|Baltimore, Maryland, United States, 21201|
|Department of Epidemiology, Johns Hopkins School of Public Health|
|Baltimore, Maryland, United States, 21205|
|United States, Mississippi|
|Jackson, Mississippi, United States, 39216|
|United States, New York|
|National Development and Research Institute|
|New York, New York, United States, 10010|
|New York Academy of Medicine|
|New York, New York, United States, 10029|
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19107|
|United States, Virginia|
|AIDS/HIV Services Group|
|Charlottesville, Virginia, United States, 22902|
|Richmond AIDS Consortium|
|Richmond, Virginia, United States, 23219|
|Cross Over Ministry|
|Richmond, Virginia, United States, 23224|